Chudley-McCullough syndrome (CMS), an autosomal recessive condition first reported by Chudley et al., in 1997 , comprises profound sensorineural hearing loss and specific brain abnormalities. The hearing loss may be congenital or early onset. Brain abnormalities are striking, but despite these brain malformations, individuals with CMS do not present significant neurodevelopmental abnormalities. Recently, the cause of CMS has been shown to be the inactivating mutations in G protein signaling modulator 2. We aimed to present a 36-year-old male who has the characteristic clinical and neuroimaging findings of CMS.
Introduction
C hudley-McCullough syndrome (CMS) is an autosomal recessively inherited disorder characterized by severe-to-profound sensorineural hearing loss and specific structural brain abnormalities. This syndrome was first recognized in a CanadianMennonite consanguineous family in which a brother and sister had hydrocephalus and profound bilateral sensorineural deafness. To date, 21 cases have been reported as having specific features of CMS. [1] [2] [3] [4] [5] [6] [7] [8] Despite striking brain malformations, individuals with CMS do not present significant neurodevelopmental abnormalities, except for hearing loss. The hearing loss may be congenital or early onset. [4, 9] Here, we present a 36-year-old male from a Turkish consanguineous family, with bilateral severe sensorineural hearing loss and characteristic brain malformations.
Case Report
A 36-year-old male with a bilateral sensorineural hearing loss was referred to the Department of Radiology for a brain magnetic resonance imaging (MRI). He is the first of two brothers born to healthy parents of Turkish descent, who are first cousins. The younger brother is healthy. There is no other family history of deafness in the extended family. At the age of 9 months, Department of Radiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey of the normal architecture, consistent with cerebellar dysplasia [ Figure 5 ]. The findings of temporal computed tomography and contrast-enhanced temporal MRI were both normal. A follow-up brain MRI study has been planned, but not performed yet.
Based on the presence of these rather specific neuroimaging findings and the history of bilateral early-onset severe sensorineural hearing loss, the patient was diagnosed as having CMS.
Discussion
After being first described in 1997, [1] several subsequent case reports further delineated the clinical phenotype of CMS. The clinical hallmarks of the syndrome are autosomal recessive inheritance, severe-to-profound sensorineural hearing loss, and partial agenesis of the corpus callosum. Distinctive combination of brain malformation, which is not seen in any other genetic syndromes, includes partial agenesis of the corpus callosum, frontal polymicrogyria, gray matter heterotopia, cerebellar dysplasia, and arachnoid cysts. [9] In 2012, Doherty et al. [9] identified biallelic mutations in G protein signaling modulator 2 (GPSM2) as the genetic cause of CMS. They investigated individuals with CMS from eight families (5 Mennonite, 1 European-American, 1 Dutch, and 1 Mexican-American family) and identified four deleterious mutations. In this study group, all of the cases had ventriculomegaly and most of them presented mild-to-moderate motor and/or communication delay. Posterior agenesis of the corpus callosum was uniformly present in all cases. Except for the two cases of whom MRI was not available, heterotopia, frontal polymicrogyria, and cerebellar dysplasia were invariable neuroimaging findings in the study group. Nearly all of the cases showed Imaging findings of four additional cases from the two families (1 Palestinian and 1 Turkish family), who had previously been reported as having nonsyndromic hearing loss and truncating mutations in GPSM2, [7, 8] were also evaluated in the study of Doherty et al. All four cases displayed imaging features consistent with CMS. However, in contrast to the other groups, none of them had ventriculomegaly, and corpus callosum abnormalities tended to be less severe. They also differed from the other groups not presenting any neurological deficits. The case we present typically showed the same clinical and neuroimaging features as these four individuals from families of Middle East origin. He had no ventriculomegaly and no neurologic disorder, and he showed the distinctive imaging findings of CMS. Our patient had rejected the genetic counseling, so the genetic nature of the disorder could not be identified.
GPSM2 is necessary for maintenance of cell polarity and spindle orientation, both of which are essential for proper tissue development. The expression of GPSM2 takes place at the apical surfaces of hair and supporting cells of inner air structures and is critical for the early development of hearing. [10] GPSM2 is also required for correct spindle orientation for neurotransmitter localization in mature neurons. [9] It has been clearly shown that inactivating mutations in GPSM2 cause CMS. [6, 9, 10] Although they have prominent structural brain abnormalities, patients with CMS do not have significant seizures or cognitive impairment. Therefore, it is recommended for all patients with sensorineural hearing loss, whether or not they have obvious signs of brain dysfunction, to be screened for GPSM2 mutations and undertake a brain imaging. Syndromic forms of corpus callosum abnormalities, including Aicardi, Apert, and Zellweger syndromes, have distinctive clinicopathologic associations which mostly present in neonates with dysmorphic findings, feeding difficulties, and/or seizures. On the other hand, nonsyndromic forms may be asymptomatic and are often associated with highly variable combinations of other central nervous system abnormalities. Therefore, CMS must be kept in mind as a differential in the cases with combined central nervous system abnormalities accompanied by sensorineural hearing loss. [11] GPSM2 sequencing in fetuses and infants with agenesis of corpus callosum and heterotopia is recommended as identification of GPSM2 mutations would greatly alter prognostic counseling and allow for early detection and treatment of hearing loss after birth. [9, 10] Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
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